期刊文献+

乳腺浸润性导管癌预后相关因素分析 被引量:7

Analysis of the factors related to prognosis of breast invasive ductal carcinoma
下载PDF
导出
摘要 目的:探讨乳腺浸润性导管癌预后相关因素。方法:收集130例乳腺浸润性导管癌资料,回顾性分析其临床特征、病理分化程度、复发转移情况、激素受体状况、人类表皮生长因子受体2的表达、临床治疗及生存情况。结果:c-erbB-2表达在ER、PR阳性组低于ER、PR阴性组(P<0.01),ER表达在PR阳性组高于PR阴性组(P<0.01);中、低分化与高分化相比,在淋巴结的转移、肿瘤的转移或复发、临床分期、肿块的大小上,均有统计学差异(P<0.05);单因素分析结果显示,激素受体状况、人类表皮生长因子受体2表达、病理分化程度、淋巴结状况、肿瘤转移或复发、临床分期、肿瘤大小、T分期、N分期、辅助化疗等11个因素与预后相关;多因素分析结果显示:ER状况、病理分化程度、淋巴结状况、临床分期是乳腺浸润性导管癌患者预后的独立影响因素。结论:对乳腺浸润性导管癌,早期发现并针对病理分化程度及激素受体水平的适当治疗是提高生存期的关键。 Objective:To investigate the factors related to prognosis of breast invasive ductal carcinoma. Methods: To analyz retrospectively the correlative clinical data including characteristics, relapse, histogical grade and survival of the patients and the expression of ER,PR,c -erbB -2 in 130 cases of breast invasive ductal carcinoma. Results : The expression of c - erbB - 2 in the group of ER or PR with positive expression was higher than that with neg- ative expression( P 〈 0.01 ). The expression of ER in the group of PR which with positive expression was higher than that with negative expression( P 〈 0.01 ) ; Grade I of breast invasive ductal carcinoma was significantly higher than grade Ⅱor Ⅲ in lymph node metastasis, clinical stage, tumor size and tumor recurrence (P 〈 0.05 ) ;The result of one - way analysis variance showed that the expression of ER, PR and c - erbB - 2, histological grade,lymph node state, tumor recurrence, tumor size, T stage, N stage, and adjuvant chemotherapy were related to prognosis ; The result of multivative COX regression showed that the expression of ER, histological grade, clinical tumor stage were the independent factors of prognosis. Conclusion: early diagnosis, treatment, histological grade and expression of endocrine are very important to enhance the survival time of breast invasive ductal carcinoma.
出处 《现代肿瘤医学》 CAS 2009年第8期1481-1483,共3页 Journal of Modern Oncology
关键词 乳腺浸润性导管症 预后因素 COX回归 breast invasive ductal cancer prognostic factor COX regression
  • 相关文献

参考文献6

二级参考文献36

  • 1田秀娟.pS2蛋白雌激素受体孕激素受体表达与乳腺癌组织学分级预后的关系[J].山西医药杂志,2005,34(4):283-285. 被引量:1
  • 2陈玲,李旭,赵新汉.乳腺癌ER,PR,c-erbB-2表达与临床病理特征的相关性分析[J].第四军医大学学报,2006,27(17):1580-1583. 被引量:11
  • 3Dowsett M,Harper-Wynne C,Boeddinghaus I,et al.HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer[J].Cancer Res,2001,61(23):8452-8458. 被引量:1
  • 4Mitter D,Ortmann O,Treeck O.Estrogen receptor beta isoforms-functions and clinical relevance in breast cancer[J].Zentralbl Gynakol,2005,127(4):228-234. 被引量:1
  • 5Lamy PJ,Verjat T,Paye M,et al.NASBA:A novel approach to assess hormonal receptors and ERBB2 status in breast cancer[J].Clin Chem Lab Med,2006,44(1):3-12. 被引量:1
  • 6Thomson CS,Hole DJ,Twelves CJ,et al.Prognositic factors in women with breast cancer:Distribution by socioeconomic status and effect on differences in survival[J].J Epidemiol Community Health,2001,55(5):308-315. 被引量:1
  • 7Ariga R,Zarif A,Korasick J,et al.Correlation of her-2/neu gene amplification with other pregnostic and predictive factors in female breast carcinoma[J].Breast J,2005,11(4):278-280. 被引量:1
  • 8Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114. 被引量:1
  • 9Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124. 被引量:1
  • 10Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583. 被引量:1

共引文献192

同被引文献55

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部